CERC News and Press, Cerecor Inc. From 05/11/21

Intec Pharma (NTEC) +25%.Ferro Corporation (FOE) +23% on Q1 results.Cerecor (CERC) +15% as FDA grants fast track designation to its CERC-002.FutureFuel Corp. (FF) +14% on special dividend.Larimar Therapeutics (LRMR) +13% on Q1 results.Advanced Emissions Solutions (ADES) +1...

Cerecor (CERC) announces that the U.S. FDA has granted Fast Track status to CERC-002 for treatment of hospitalized patients with COVID-19.The company's shares were up 15% during premarket trading.CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor nec...

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administr...

Initial data anticipated in the third quarter of 2021 Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROO...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are unique . They don’t really follow the rules of other stocks. Earnings don’t matter much. Media coverage doesn’t matter much. Current valuation multiples don’t matter much....

Alterity Therapeutics (ATHE) +22%.Welbilt (WBT) +19% on being acquired by The Middleby Corp.Sierra Metals (SMTS) +12%.Williams Industrial Services (WLMS) +12%.Uxin Limited (UXIN) +9%.inTEST Corporation (INTT) +8%.Ocugen (OCGN) +7%.Energy Recover (ERII) +7%.Cerecor (CERC) +6%.Aesthetic Me...

CERC-002, a monoclonal antibody (mAB) from Cerecor (CERC), reduced respiratory failure and death in a small trial of hospitalized COVID-19 patients.Results, published as a preprint in medRxiv and not yet peer reviewed, found that 83.9% of patients with acute respiratory distress syndrome give...

Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody for all indications. Under the terms of agreement, Kyow...

Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS) Kyowa Kirin Co. has an option to retain the rights for all ...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...